Recently, the State Administration of Pharmaceutical Products announced 20 batches of unqualified drugs from 10 pharmaceutical manufacturers.
These include:
The 12 batches of Dendrobium luminous pills labeled as Jilin Tonghua Xiang Bo Pharmaceutical Co., Ltd., Jilin Shuangshi Pharmaceutical Co., Ltd. and Jilin Tiantai Pharmaceutical Co., Ltd. did not meet the requirements, and the unqualified items were marked.
After inspection by Shanxi Food and Drug Inspection Institute, 1 batch of clarithromycin sustained-release tablets labeled as Hainan Puli Pharmaceutical Co., Ltd. did not meet the requirements, and the unqualified item was loss on drying. In addition, the 1 batch of azlocillin sodium for injection produced by Shanxi Ganyuan Pharmaceutical Group Co., Ltd. did not meet the requirements, the two batches of compound honeysuckle granules produced by Hebei Guo Jin Pharmaceutical Co., Ltd. and Guangzhou Huacheng Pharmaceutical Co., Ltd. did not meet the requirements, and the 1 batch of Rhodiola sachalinensis and 1 batch of Radix Peucedani produced by anguo city Tongkang Pharmaceutical Co., Ltd. did not meet the requirements.
In these drugs, either loss on drying is inconsistent, or the differences in nature and weight are inconsistent.
In fact, the formula of these drugs has a core standard, that is, China Pharmacopoeia. China Pharmacopoeia contains a lot of information about chemicals, biopharmaceuticals and Chinese herbal medicines. The source, production technology, weight difference, related identification and indications of these drugs are introduced in detail.
As long as the manufacturer strictly follows the above requirements, sometimes it can be higher than the above standards, which is absolutely no problem. Some of them may be cheating, but more should be that they are not very strict in the process of giving birth.
I hope they can strictly follow the standards.